Project description
Europe joins forces to tackle COVID-19
Convalescent plasma (CP) from recovered COVID-19 patients is being considered as a potential treatment. The EU-funded SUPPORT-E project aims to support high quality clinical evaluation of COVID-19 CP as well as data collection and analysis. It also strives to improve CP potency assessment, develop evidence-based recommendations on the appropriate use of CP for the treatment of COVID-19 across EU Member States and promote best practices regarding CP collection and use in the current health crisis as well as in subsequent crises involving novel pathogens. By bringing together major European blood establishments with world leading research capabilities, SUPPORT-E constitutes the first EU coordinated research effort to support high quality clinical and scientific evaluation of COVID-19 CP.
Objective
Coronavirus disease 19 (COVID-19) is provoking the greatest global health crisis of this generation. With no vaccine or specific antiviral treatment available to date, the use of convalescent plasma (CP) from recovered COVID-19 patients has been considered a potential curative strategy. To demonstrate its efficacy and safety, clinical studies are ongoing or planned in various EU Member States. Unfortunately, there lacks a coordinated approach involving a large number of blood establishments (BEs) and clinical centres to harmonise protocols and guidelines, to standardise assays for characterising the potency of the plasma and to validate clinical outcome which will be of great importance to ensure that significant conclusions can be drawn. SUPPORT-E brings together major European BEs with world leading research capabilities with the aim to support high quality clinical and scientific evaluation of COVID-19 CP (CCP) and thereby achieve a consensus on the appropriate use of CCP in the treatment of COVID-19 across EU Member States. Hence, SUPPORT-E will advance the current state-of-the-art by delivering the much needed harmonised evidence-based recommendations with respect to the use of CPP in clinical trials and monitored access programmes for COVID-19 patients in Europe. Further, standardised informative in vitro assays providing scientific insights that could support such recommendations will also be developed. SUPPORT-E offers an EU-wide collaboration between Member States, BEs and clinical centres in order to close the knowledge gap and to ensure applicability of the recommendations for all EU Members States. SUPPORT-E represents the first European Union coordinated research effort on passive immunotherapy, sharing data and protocols in real-time and pooling efforts to decrease the time as much as possible for validating CCP as a valid therapeutic treatment and also providing a basis for further optimisation by combined approaches with other anti-viral treatments.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences health sciences infectious diseases RNA viruses coronaviruses
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences basic medicine immunology immunotherapy
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3.1.3. - Treating and managing disease
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
RIA - Research and Innovation action
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-IBA-SC1-CORONAVIRUS-2020-3
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
1066 CX Amsterdam
Netherlands
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.